Cargando…

MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas

Aurora kinases have become an attractive target in cancer therapy due to their deregulated expression in human tumors. Liposarcoma, a type of soft tissue sarcoma in adults, account for approximately 20% of all adult soft tissue sarcomas. There are no effective chemotherapies for majority of these tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nair, Jayasree S., Schwartz, Gary K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914329/ https://www.ncbi.nlm.nih.gov/pubmed/26887042 http://dx.doi.org/10.18632/oncotarget.7335

Ejemplares similares

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
por: Sells, Todd B., et al.
Publicado: (2015)

Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237
por: Tayyar, Yaman, et al.
Publicado: (2019)

The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy
por: Asteriti, Italia Anna, et al.
Publicado: (2014)

A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma
por: Zhang, Kai, et al.
Publicado: (2018)

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
por: Carol, Hernan, et al.
Publicado: (2011)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
por: Falchook, Gerald S., et al.
Publicado: (2015)

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
por: Goldberg, Stuart L., et al.
Publicado: (2014)

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
por: Kelly, Kevin R, et al.
Publicado: (2011)

Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells
por: Yang, Yan, et al.
Publicado: (2020)

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
por: Gay, Carl M., et al.
Publicado: (2020)

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
por: Kelly, Kevin R., et al.
Publicado: (2013)

The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G(2)/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells
por: Li, Jin-Ping, et al.
Publicado: (2015)

Domain-specific interactions between MLN8237 and human serum albumin estimated by STD and WaterLOGSY NMR, ITC, spectroscopic, and docking techniques
por: Yang, Hongqin, et al.
Publicado: (2017)

Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway
por: Niu, Ning-Kui, et al.
Publicado: (2015)

Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth
por: Kannan, Aarthi, et al.
Publicado: (2015)

Effects of the NEDD8-Activating Enzyme Inhibitor MLN4924 on Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus
por: Chang, Pey-Jium, et al.
Publicado: (2017)

Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment
por: Misra, Shrilekha, et al.
Publicado: (2020)

Broad and potent antiviral activity of the NAE inhibitor MLN4924
por: Le-Trilling, Vu Thuy Khanh, et al.
Publicado: (2016)

Immune checkpoint inhibitor resistance in soft tissue sarcoma
por: Eulo, Vanessa, et al.
Publicado: (2022)

Discovery of a novel Aurora B inhibitor GSK650394 with potent anticancer and anti-aspergillus fumigatus dual efficacies in vitro
por: He, Yuhua, et al.
Publicado: (2021)

Soft-tissue Sarcomas
por: Vodanovich, Domagoj Ante, et al.
Publicado: (2018)

Aurora B Inhibitors as Cancer Therapeutics
por: Kovacs, Antal H., et al.
Publicado: (2023)

Dual roles of oxostephanine as an Aurora kinase inhibitor and angiogenesis suppressor
por: Tran, Thu-Hien Thi, et al.
Publicado: (2022)

The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors
por: Bahjat, Mahnoush, et al.
Publicado: (2019)

Adjuvant radiotherapy with brachytherapy boost in soft tissue sarcomas
por: Cortesi, Annalisa, et al.
Publicado: (2017)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
por: Malhab, Lara J. Bou, et al.
Publicado: (2016)

Ewing sarcoma of the facial soft tissues—a case report
por: Knight, Beau, et al.
Publicado: (2022)

Epidemiological study of soft‐tissue sarcomas in Ireland
por: Bhatt, Nikita, et al.
Publicado: (2015)

Retroperitoneal soft tissue sarcoma
por: Zepeda, Ernesto, et al.
Publicado: (2007)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Soft Tissue Sarcomas of the Kidney
por: Köhle, Olivia, et al.
Publicado: (2015)

Bone and Soft Tissue Sarcoma
por: Ruggiero, Antonio
Publicado: (2020)

Trabectedin for soft tissue sarcoma
Publicado: (2021)

Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas
por: Loong, Herbert H., et al.
Publicado: (2018)

Photodynamic Therapy Using Hippo Pathway Inhibitor Verteporfin: A Potential Dual Mechanistic Approach in Treatment of Soft Tissue Sarcomas
por: Rytlewski, Jeffrey D., et al.
Publicado: (2021)

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
por: Wolenski, F S, et al.
Publicado: (2015)

Neddylation inhibitor MLN4924 suppresses cilia formation by modulating AKT1
por: Mao, Hongmei, et al.
Publicado: (2019)

The MLN4924 inhibitor exerts a neuroprotective effect against oxidative stress injury via Nrf2 protein accumulation
por: Andérica-Romero, Ana Cristina, et al.
Publicado: (2016)

Development of a radiosensitivity gene signature for patients with soft tissue sarcoma
por: Tang, Zaixiang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_22qpt44bh130pd701oaghc6h1g